FY2021 EPS Estimates for Eli Lilly and Co (LLY) Decreased by Jefferies Group

Eli Lilly and Co (NYSE:LLY) – Analysts at Jefferies Group decreased their FY2021 EPS estimates for Eli Lilly and in a research note issued to investors on Tuesday. Jefferies Group analyst J. Holford now expects that the company will post earnings of $6.75 per share for the year, down from their previous forecast of $6.77. Jefferies Group has a “Buy” rating and a $100.00 price objective on the stock. Jefferies Group also issued estimates for Eli Lilly and’s FY2022 earnings at $7.42 EPS.

Several other equities analysts have also weighed in on the stock. Goldman Sachs Group lowered shares of Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their target price for the company from $86.98 to $95.00 in a report on Tuesday. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and lifted their target price for the company from $85.52 to $115.00 in a report on Friday, January 5th. Credit Suisse Group restated a “hold” rating on shares of Eli Lilly and in a report on Wednesday, December 13th. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, December 12th. Finally, Morgan Stanley lifted their target price on shares of Eli Lilly and from $86.00 to $90.00 and gave the company an “equal weight” rating in a report on Tuesday, November 21st. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $92.75.

Eli Lilly and (NYSE:LLY) traded down $0.39 during trading hours on Wednesday, hitting $85.82. 4,445,813 shares of the company traded hands, compared to its average volume of 3,320,000. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. The firm has a market cap of $94,500.00, a price-to-earnings ratio of 40.87, a price-to-earnings-growth ratio of 1.60 and a beta of 0.35. Eli Lilly and has a 1-year low of $74.00 and a 1-year high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the business earned $0.88 EPS.

Institutional investors have recently added to or reduced their stakes in the stock. Private Trust Co. NA increased its position in shares of Eli Lilly and by 9.4% in the 2nd quarter. Private Trust Co. NA now owns 8,518 shares of the company’s stock worth $700,000 after purchasing an additional 731 shares during the last quarter. New England Research & Management Inc. bought a new stake in shares of Eli Lilly and in the 2nd quarter worth about $354,000. Appleton Partners Inc. MA increased its position in shares of Eli Lilly and by 4.9% in the 2nd quarter. Appleton Partners Inc. MA now owns 7,001 shares of the company’s stock worth $576,000 after purchasing an additional 325 shares during the last quarter. Bank of Montreal Can increased its position in shares of Eli Lilly and by 66.9% in the 2nd quarter. Bank of Montreal Can now owns 1,508,937 shares of the company’s stock worth $124,186,000 after purchasing an additional 604,577 shares during the last quarter. Finally, First Financial Bank Trust Division increased its position in shares of Eli Lilly and by 11.3% in the 2nd quarter. First Financial Bank Trust Division now owns 5,705 shares of the company’s stock worth $469,000 after purchasing an additional 578 shares during the last quarter. 76.35% of the stock is currently owned by hedge funds and other institutional investors.

In related news, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the sale, the senior vice president now owns 54,885 shares of the company’s stock, valued at approximately $4,729,989.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction on Friday, November 10th. The stock was sold at an average price of $83.67, for a total transaction of $167,591.01. Following the sale, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders have sold a total of 251,088 shares of company stock worth $22,041,236 in the last ninety days. 0.20% of the stock is currently owned by insiders.

The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Investors of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date is Wednesday, February 14th. This represents a $2.25 annualized dividend and a yield of 2.62%. Eli Lilly and’s payout ratio is 99.05%.

TRADEMARK VIOLATION WARNING: “FY2021 EPS Estimates for Eli Lilly and Co (LLY) Decreased by Jefferies Group” was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://transcriptdaily.com/2018/01/19/fy2021-eps-estimates-for-eli-lilly-and-co-lly-decreased-by-jefferies-group.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Earnings History and Estimates for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply